A Brief Update on the Management of Hepatitis Delta

  • Nayantara Orekondy
  • Eric R. KallwitzEmail author
Invited Commentary

Hepatitis Delta

Hepatitis delta (HDV) is an incomplete virus requiring hepatitis B (HBV), specifically hepatitis B surface antigen (HBsAg) to replicate. HDV can present as an acute or chronic infection and has been described as the most severe chronic viral hepatitis [1]. HDV has a seroprevalence of approximately 5% of persons with chronic HBV with an estimated 15–20 million people infected with HDV worldwide [2, 3]. Fortunately, the number of HDV-infected persons has decreased since the 1990s due to the successful global HBV vaccination program [4]. The only approved treatment agent for HDV is interferon (IFN)-α; however, pegylated interferon is the current standard of care. Interferon-based therapy is limited by poor response, high rates of relapse, and adverse effects [5, 6]. Presently, there are three novel therapies that are being evaluated for chronic HDV infection, lonafarnib [7], REP2139-CA [8], and myrcludex B [1, 9]. Given the severity of HDV, newer and more effective...


  1. 1.
    Chen H-Y, Shen D-T, Ji D-Z, Han P-C, Zhang W-M, Ma J-F, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018;18Google Scholar
  2. 2.
    Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997–1003.CrossRefGoogle Scholar
  3. 3.
    “Hepatitis D” World Health Organization, World Health Organization, July 2018,
  4. 4.
    Casey RM, Dumolard L, Danovaro-Holliday MC, Gacic-Dobo M, Diallo MS, Hampton LM, et al. Global routine vaccination coverage, 2015. MMWR Morb Mortal Wkly Rep. 2016 Nov 18;65(45):1270–3.CrossRefGoogle Scholar
  5. 5.
    Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994 Jan 13;330(2):88–94.CrossRefGoogle Scholar
  6. 6.
    Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014 Jul 1;60(1):87–97.CrossRefGoogle Scholar
  7. 7.
    Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167–74.CrossRefGoogle Scholar
  8. 8.
    Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2(12):877–89.CrossRefGoogle Scholar
  9. 9.
    Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13(10):580–9.CrossRefGoogle Scholar
  10. 10.
    Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014 Jan;16(1):365.CrossRefGoogle Scholar
  11. 11.
    Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int Off J Int Assoc Study Liver. 2011 Jan;31(1):7–21.CrossRefGoogle Scholar
  12. 12.
    Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet Lond Engl. 2011 Jul 2;378(9785):73–85.CrossRefGoogle Scholar
  13. 13.
    Lin H-H, Lee SS-J, Yu M-L, Chang T-T, Su C-W, Hu B-S, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015 Jun 1;61(6):1870–9.CrossRefGoogle Scholar
  14. 14.
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008 Feb;48(2):335–52.CrossRefGoogle Scholar
  15. 15.
    Govindarajan S, De Cock KM, Redeker AG. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatol Baltim Md. 1986 Aug;6(4):640–4.CrossRefGoogle Scholar
  16. 16.
    Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560–99.CrossRefGoogle Scholar
  17. 17.
    Farci P, Anna NG. Current and future management of chronic hepatitis D. Gastroenterol Hepatol. 2018 Jun;14(6):342–51.Google Scholar
  18. 18.
    Samiullah S, Bikharam D, Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. 2012;18(40):5793–8.CrossRefGoogle Scholar
  19. 19.
    Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27;364(4):322–31.CrossRefGoogle Scholar
  20. 20.
    Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8.CrossRefGoogle Scholar
  21. 21.
    Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018 Apr 1;68:S3.CrossRefGoogle Scholar
  22. 22.
    Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018 Apr 1;67(4):1224–36.CrossRefGoogle Scholar
  23. 23.
    Yurdaydin C, Idilman R, Keskin O, Kalkan C, Karakaya MF, Caliskan A, et al. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study. J Hepatol. 2017 Jan 1;66(1):S33–4.CrossRefGoogle Scholar
  24. 24.
    Koh C, Surana P, Han T, Fryzek N, Kapuria D, Etzion O, et al. A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study. J Hepatol. 2017 Jan 1;66(1):S101–2.CrossRefGoogle Scholar
  25. 25.
    Wedemeyer H, Port K, Deterding K, Wranke A, Kirschner J, Bruno B, et al. A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study. J Hepatol. 2017 Jan 1;66(1):S24.CrossRefGoogle Scholar
  26. 26.
    Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One. 2015;10(11):e0140909.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Loyola University Medical CenterMaywoodUSA

Personalised recommendations